ROIV vs. TEVA, ALNY, GMAB, RPRX, BMRN, BGNE, VTRS, SRPT, UTHR, and RDY
Should you be buying Roivant Sciences stock or one of its competitors? The main competitors of Roivant Sciences include Teva Pharmaceutical Industries (TEVA), Alnylam Pharmaceuticals (ALNY), Genmab A/S (GMAB), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), BeiGene (BGNE), Viatris (VTRS), Sarepta Therapeutics (SRPT), United Therapeutics (UTHR), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical preparations" industry.
Roivant Sciences (NASDAQ:ROIV) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, community ranking, profitability and analyst recommendations.
Teva Pharmaceutical Industries received 1270 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 75.44% of users gave Roivant Sciences an outperform vote while only 67.61% of users gave Teva Pharmaceutical Industries an outperform vote.
Roivant Sciences has a net margin of 3,484.86% compared to Teva Pharmaceutical Industries' net margin of -2.88%. Teva Pharmaceutical Industries' return on equity of 37.33% beat Roivant Sciences' return on equity.
64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 4.6% of Roivant Sciences shares are held by company insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Roivant Sciences presently has a consensus target price of $16.90, indicating a potential upside of 63.13%. Teva Pharmaceutical Industries has a consensus target price of $15.75, indicating a potential downside of 6.97%. Given Roivant Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Roivant Sciences is more favorable than Teva Pharmaceutical Industries.
In the previous week, Teva Pharmaceutical Industries had 2 more articles in the media than Roivant Sciences. MarketBeat recorded 20 mentions for Teva Pharmaceutical Industries and 18 mentions for Roivant Sciences. Teva Pharmaceutical Industries' average media sentiment score of 0.31 beat Roivant Sciences' score of 0.13 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.
Teva Pharmaceutical Industries has higher revenue and earnings than Roivant Sciences. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
Roivant Sciences has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.
Summary
Roivant Sciences beats Teva Pharmaceutical Industries on 11 of the 18 factors compared between the two stocks.
Get Roivant Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ROIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roivant Sciences Competitors List
Related Companies and Tools
